Clinical trial D5164C00001 ADAURA
A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)
Cancers | |
---|---|
Organ | NSCLC |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | AstraZeneca |
EudraCT Identifier | 2015-000662-65 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02511106 |
Inclusion criteria | EGFR mutation : Ex19del, L858R, alone or in combination with T790M mutation. |
Last update |